[{"orgOrder":0,"company":"InnoUp Farma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"INP12","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"InnoUp Farma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"InnoUp Farma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"InnoUp Farma \/ Undisclosed"},{"orgOrder":0,"company":"InnoUp Farma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SPAIN","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"INP20","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"InnoUp Farma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"InnoUp Farma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"InnoUp Farma \/ Undisclosed"}]

Find Clinical Drug Pipeline Developments & Deals by InnoUp Farma

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : INP12 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          September 19, 2024

                          Lead Product(s) : INP12

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : INP20 is a drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Peanut Hypersensitivity.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          November 14, 2019

                          Lead Product(s) : INP20

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank